Friday, November 1, 2013

AASLD: President's Press Conference Will Take Place On Saturday November 2 2013

Related @ Healio
Annual Liver Meeting begins this weekend will present live coverage of the American Association for the Study of Liver Diseases’ annual Liver Meeting running through Tuesday in Washington.

AASLD President's Press Conference 

Saturday, November 2, 2013 – 4:00-5:00 pm
Room 150B, Walter E. Washington Convention Center

AASLD President J. Gregory Fitz, MD, will host a press conference on the first full day of presentations at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases.

Dr. Fitz will highlight individual studies and themes from the 2306 abstracts to be presented at this year's meeting from the leading researchers in the field. He has selected to review 13 abstracts in advance of their actual presentation in scientific sessions for the benefit of the media:

Hepatitis C Virus Screening and Prevalence among US Veterans in Department of Veterans Affairs Care in 2012
Screening in Emergency Department Identifies a Large Cohort of Unrecognized Chronic Hepatitis C Virus Infection among Baby Boomers
Impact of Treatment on Long-Term Morbidity and Mortality in Chronic Hepatitis C Patients Receiving Care Through the U.S. Veterans Health Administration
Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naïve patients with chronic HCV genotype 1 infection
IFNL4-ΔG Genotype and Racial Differences in Treatment Response in Virahep-C
Telaprevir combination therapy in treatment-naïve and experienced patients co-infected with HCV and HIV
Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection after Liver Transplantation
Integrative genomic profiling of hepatocellular adenomas identify mutational processes involved in malignant transformation
Interim analysis of hepatitis B reactivation in patients with prior HBV exposure undergoing rituximab-containing chemotherapy: a prospective study
High-dose corticosteroid therapy following portoenterostomy in infants with biliary atresia does not improve outcome: The multi-center, randomized, double-blind, placebo-controlled START Trial
Hepatocyte-derived metabolic danger signals, extracellular ATP and uric acid, synergistically induce inflammatory cell activation and represent therapeutic targets in alcoholic liver disease
Binge Drinking and Weight Gain Accentuate Eicosanoid Mediated Inflammation and Oxidative Injury in Alcoholic Liver Disease – Novel Pathophysiologic Insights from Lipidomic Analysis
Medication Tradeoffs, Non-Adherence, and Clinical Outcomes among Liver Transplant Recipients About Dr. Fitz

Dr. Fitz is the Donald W. Seldin Distinguished professor and chair of the Department of Internal Medicine at the University of Texas Southwestern (UTSW) School of Medicine. He has been named dean of the UT Southwestern School of Medicine and provost of the medical center, effective October 1, 2009. He received his medical degree from Duke University, and then spent 10 years at the University of California San Francisco (UCSF) as a resident, fellow, and faculty member. Subsequently he returned to Duke where he was active in liver transplantation, clinical hepatology, and basic research. Later he moved to the University of Colorado Health Science Center as the Waterman Professor of Liver Research and Chief of the Division of Gastroenterology and Hepatology. He has been Chairman of Internal Medicine at UTSW since 2003.

The research interests of Dr. Fitz's laboratory focus on the cellular mechanisms responsible for regulation of the number, type and activity of ion channels in liver cells; and on the role of ATP as an autocrine/paracrine signal regulating bile formation and other liver functions. The long term goals of these studies are to better define the cellular strategies for i) coupling cell metabolism to ion transport, ii) treatment of liver injury in conditions where cell volume regulation appears to be impaired, and iii) regulation of cholangiocytes secretion as a key contributor to the bile secretory unit. These ongoing studies have been supported by the National Institutes of Health for ~20 years, including an active MERIT award.

Dr. Fitz has substantial administrative and organizational experience, including participation in private foundations and NIH study sections. He is a member of the American Society for Clinical Investigation and the Association of American Physicians as well as numerous specialty societies. He has served as Associate Editor of HEPATOLOGY and in other editorial positions, and as Chairman of the Research Committee of the AGA, co-director of national courses in Gastroenterology (AGA) and Hepatology (AASLD), and president of the Gastroenterology Research Group. He continues to be involved actively in medical education of residents, fellows and faculty.


Founded in 1950, AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD has grown into an international society responsible for all aspects of hepatology, and the annual meeting attracts 9,500 physicians, surgeons, researchers, and allied health professionals from around the world.

The Liver Meeting® is the premier meeting in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies.

Contact: Please click here to obtain a press pass for this event. Press releases and all abstracts are available online at

No comments:

Post a Comment